Acute promyelocytic leukemia (APL) cells exhibit disrupted regulation of cell death and
differentiation, and therefore the fate of these leukemic cells is unclear. Here, we provide the …

Autophagy is one of the main cellular catabolic pathways controlling a variety of
physiological processes, including those involved in self-renewal, differentiation and death …

Despite the high efficacy and safety of arsenic trioxide (ATO) in treating acute promyelocytic
leukemia (APL) and eradicating APL leukemia-initiating cells (LICs), the mechanism …

Acute promyelocytic leukemia (APL) results from a blockade of granulocyte differentiation at
the promyelocytic stage. All-trans retinoic acid (ATRA) induces clinical remission in APL …

PML-RARα oncoprotein is a fusion protein of promyelocytic leukemia (PML) and the retinoic
acid receptor-α (RARα) and causes acute promyelocytic leukemias (APL). A hallmark of all …

Despite advances in the treatment of acute myeloid leukemia (AML), relapse and drug
resistance frequently occur. Therefore, detailed mechanisms of refractoriness, including …

Acute promyelocytic leukemia (APL) is characterized by a chromosomal t (15; 17)
translocation that fuses the gene encoding the promyelocytic leukemia protein (PML) to that …

Highlights•Autophagy is increased during all-trans-retinoic acid-induced differentiation of
NB4 leukemia cells.•Inhibition (small hairpin RNA) of an essential autophagy gene ATG7 …

The role of autophagy during leukemia treatment is unclear. On the one hand, autophagy
might be induced as a prosurvival response to therapy, thereby reducing treatment …

Acute promyelocytic leukemia (APL) is characterized by the t (15; 17)-associated PML-
RARA fusion gene. We have previously found that MIR125B1 is highly expressed in patients …